Loading clinical trials...
Loading clinical trials...
Treatment of Morbid Obesity by Intragastric Injections of Botulinum Toxin A. A Randomized, Double-blind, Placebo Controlled, Phase II-trial
One possible angle for treating obesity could be slowing down the gastric emptying time. By prolonging the gastric emptying time, the person would ideally experience increased sensation of satiety, and in the long run reduce food intake. If such a treatment provides a clinically significant weight loss, this could be an alternative for surgical procedures, avoiding the risk for perioperative complications as well as complications in the long run. There are now several pilot studies documenting that intragastric treatment with botulinum toxin A (BTA) can be effective, although the treatment perspective is short and do not include repeated injections. However, they demonstrate that BTA-injections are safe for the patient. The treatment is administered by endoscopy.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
St. Olavs Hospital, Trondheim University Hospital
Trondheim, Norway
Start Date
February 1, 2014
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2022
Last Updated
October 10, 2022
20
ACTUAL participants
Botulinum Toxin Type A
DRUG
Saline solution
DRUG
Lead Sponsor
Norwegian University of Science and Technology
Collaborators
NCT03868592
NCT05242835
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05918575